PSMA PET/CT 在肾细胞癌分期与再分期中的效用:系统综述与荟萃分析
该系统综述与荟萃分析检索 PubMed、Embase 及摘要会议录(最后更新至 2023 年 8 月),纳入 9 项研究共 152 例患者(133 例透明细胞肾细胞癌,19 例其他亚型),评估 PSMA PET/CT 在肾细胞癌分期或再分期中的病灶检出率。汇总检出率为 0.83(95%CI 0.67-0.92),原发肾细胞癌评估为 0.74(95%CI 0.57-0.86),转移或复发再分期为 0.87(95%CI 0.73-0.95)。作者认为 PSMA PET/CT 可能是有前景的替代影像方法,尤其对转移性透明细胞肾细胞癌,但需大型前瞻性研究确认。
要点
- PSMA PET/CT 评估原发或转移性肾细胞癌的汇总病灶检出率为 0.83(95%CI 0.67-0.92)。
- 原发肾细胞癌分期或评估的汇总检出率为 0.74(95%CI 0.57-0.86),转移或复发再分期为 0.87(95%CI 0.73-0.95)。
- 转移性透明细胞肾细胞癌中,现有数据支持 18F-DCFPyL PET/CT 检出率显著高于传统影像(2 项研究)。
核心结论
- 作者初步结果显示 PSMA PET/CT 可能是评估肾细胞癌的有前景的替代影像方法,尤其对转移性透明细胞肾细胞癌。
- 作者指出需大型前瞻性研究确认其在肾细胞癌分期与再分期中的临床效用。
研究设计与样本
- 系统综述与荟萃分析,检索 PubMed、Embase 及摘要会议录,最后更新至 2023 年 8 月。
- 纳入提供 PSMA 放射性示踪剂在肾细胞癌分期或再分期中病灶检出率的研究进入荟萃分析。
- 共纳入 9 项研究、152 例患者,其中透明细胞肾细胞癌 133 例,其他肾细胞癌亚型 19 例。
主要发现
- PSMA PET/CT 评估原发或转移性肾细胞癌的汇总检出率为 0.83(95%CI 0.67-0.92)。
- 原发肾细胞癌病灶分期或评估的汇总 PSMA 检出率为 0.74(95%CI 0.57-0.86)。
- 转移或复发肾细胞癌再分期的汇总 PSMA 检出率为 0.87(95%CI 0.73-0.95)。
- 68Ga 标记 PSMA 示踪剂的汇总检出率为 0.85(95%CI 0.62-0.95),18F-DCFPyL PET/CT 为 0.92(95%CI 0.76-0.97)。
- 在转移性透明细胞肾细胞癌中,现有数据支持 18F-DCFPyL PET/CT 检出率显著高于传统影像方法(2 项研究)。
临床怎么用
- 作者初步结果提示 PSMA PET/CT 可能是评估肾细胞癌、尤其转移性透明细胞肾细胞癌的有前景的替代影像方法。
- 作者指出需大型前瞻性研究确认 PSMA PET/CT 在肾细胞癌分期与再分期中的临床效用。
局限性
- 作者称其为初步结果。
- 作者指出需大型前瞻性研究确认临床效用。
- 18F-DCFPyL PET/CT 与传统影像比较的数据仅来自 2 项研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of multiple solid tumors, including renal cell carcinoma (RCC). Studies have demonstrated promising results on the utility of PSMA-targeted PET/CT imaging in RCC. This report aims to provide a systematic review and metaanalysis on the utility and detection rate of PSMA PET/CT imaging in staging or evaluation of primary RCC and restaging of metastatic or recurrent RCC. Methods: Searches were performed in PubMed, Embase, and abstract proceedings (last updated, August 2023). Studies that provided a lesion-level detection rate of PSMA radiotracers in staging or restaging of RCC were included in the metaanalysis. The overall pooled detection rate with a 95% CI was estimated, and subgroup analysis was performed when feasible. Results: Nine studies comprising 152 patients (133 clear cell RCC [ccRCC], 19 other RCC subtypes) were included in the metaanalysis. The pooled detection rate of PSMA PET/CT in evaluation of primary or metastatic RCC was estimated to be 0.83 (95% CI, 0.67-0.92). Subgroup analysis showed a pooled PSMA detection rate of 0.74 (95% CI, 0.57-0.86) in staging or evaluation of primary RCC lesions and 0.87 (95% CI, 0.73-0.95) in restaging of metastatic or recurrent RCC. Analysis based on the type of radiotracer showed a pooled detection rate of 0.85 (95% CI, 0.62-0.95) for 68Ga-based PSMA tracers and 0.92 (95% CI, 0.76-0.97) for 18F-DCFPyL PET/CT. Furthermore, in metastatic ccRCC, the available data support a significantly higher detection rate for 18F-DCFPyL PET/CT than for conventional imaging modalities (2 studies). Conclusion: Our preliminary results show that PSMA PET/CT could be a promising alternative imaging modality for evaluating RCC, particularly metastatic ccRCC. Large prospective studies are warranted to confirm clinical utility in the staging and restaging of RCC.
引用
- Sadaghiani MS, Baskaran S, Gorin MA, et al. Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis. J Nucl Med. 2024. PMID: 38782453. doi:10.2967/jnumed.124.267417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。